SCHEMBL30714647

SCHEMBL30714647

CN(C)C1(CNC(=O)c2c3cc(OCc4ccccc4)ccc3nn2C)CCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A5 Q9Y345 4/20 0.51
TP53 P04637 1/20 0.43
HTR3A P46098 2/20 0.43
NMT1 P30419 2/20 0.41
THRB P10828 2/20 0.41
CHRNB2 P17787 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
CHRNA4 P43681 1/20 0.40
MMP13 P45452 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 1/20 0.38
HDAC3 O15379 1/20 0.38
APP P05067 1/20 0.38
ACHE P22303 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714688 0.86 TP53 (0.40) SLC6A5TP53THRBCHRNB2CHRNB4
SCHEMBL30714558 0.84 SLC6A5 (0.40) SLC6A5TP53THRBCHRNB2CHRNB4
SCHEMBL30714706 0.83 CHRNB2 (0.42) SLC6A5TP53THRBCHRNB2CHRNB4
SCHEMBL30714727 0.81 HTR3A (0.44) HTR3ANMT1MMP13MEN1KMT2A
SCHEMBL30714674 0.80 HTR3A (0.43) HTR3ANMT1MMP13MEN1KMT2A
SCHEMBL30714748 0.80 HTR3A (0.43) HTR3ANMT1MMP13MEN1KMT2A
SCHEMBL26696088 0.78 SRD5A2 (0.50) NMT1MEN1KMT2A
SCHEMBL30714592 0.78 EGLN2 (0.45) HTR3ANMT1MMP13MEN1KMT2A
SCHEMBL31539883 0.77 HTR3A (0.41) HTR3ANMT1MMP13MEN1KMT2A
SCHEMBL30714607 0.76 MMP13 (0.47) HTR3ANMT1MMP13MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 SLC6A5 904/4885TP53 4201/4885HTR3A 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.